AZ signs agreement for targeted drug delivery research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Natali_mis)
(Image: Getty/Natali_mis)

Related tags: Drug delivery, Drug delivery systems, Research, Astrazeneca, Drug delivery technologies, Peptide, Kidney, Technology

AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.

According to Aptamer, its proprietary technology can be used to determine the feasibility of developing “next generation”​ drug delivery vehicles: Aptamer Drug Conjugates (ApDCs).

Aptamer CEO Arron Tolley told us, “The deal is a significant landmark in the evolution of the company. This deal is a clear demonstration that the technology platform we have developed is being recognized as a superior alternative to current antibody technology.”

The two-year collaboration, Aptamer’s platform technology with AstraZeneca’s experience in cardiovascular, renal and metabolism (CRVM) therapy development, as well as its experience in drug discovery and development. The goal is to use ApDCs to enable targeted delivery to the kidney.

According to AstraZeneca, working with oligonucleotides for targeted drug delivery has posed many challenges previously.

ApDC’s are oligonucleotide or peptide molecules that bind to a target molecule and fold into secondary or tertiary structures. Due to the molecule's mechanism, they have the ability to bind to cell-specific targets and can be attached to therapeutic compounds for target drug delivery. 

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more